Table 3.
Quality of life scores (mean ± SD) by TNM stage, type of treatment.
| EORTC Items | TNM stage | P | Type of treatment | P | ||||
|---|---|---|---|---|---|---|---|---|
| 0-I | II | III | IV | Chemotherapy only | Others | |||
| Panel A: QLQ-C30 Questionnaire | ||||||||
|
| ||||||||
| GHS | 55.1±13.3 | 54.0±15.8 | 52.6±15.1 | 53.9±14.0 | 0.497 | 51.8±12.8 | 55.6±15.9 | <0.001∗ |
| Functional scales | ||||||||
| PF | 75.5±17.2 | 78.5±15.1 | 74.4±18.0 | 73.0±18.4 | 0.068 | 78.5±16.2 | 72.8±17.7 | <0.001∗ |
| RF | 76.9±25.0 | 81.1±25.2 | 76.2±25.4 | 74.4±27.5 | 0.112 | 81.0±23.3 | 74.1±27.0 | 0.001∗ |
| EF | 75.0±18.3 | 77.0±19.5 | 72.3±20.6 | 72.7±20.3 | 0.170 | 75.9±18.7 | 72.7±20.5 | 0.052 |
| CF | 78.2±18.1 | 79.2±17.4 | 74.8±21.8 | 75.3±18.7 | 0.303 | 79.0±18.3 | 74.9±20.3 | 0.012∗ |
| SF | 71.5±25.8 | 71.8±22.8 | 68.6±25.3 | 66.2±22.6 | 0.180 | 71.5±23.5 | 68.5±25.5 | 0.118 |
| Symptom scales | ||||||||
| FA | 34.4±16.4 | 30.9±18.3 | 35.0±18.5 | 36.2±19.8 | 0.017∗ | 32.0±16.1 | 35.8±19.5 | 0.016∗ |
| NV | 19.5±21.2 | 14.0±18.6 | 20.9±23.2 | 21.7±20.7 | 0.010∗ | 15.0±19.1 | 22.6±22.8 | <0.001∗ |
| DI | 10.5±18.2 | 7.5±16.1 | 12.2±21.5 | 10.5±16.5 | 0.211 | 7.5±16.0 | 13.0±20.8 | 0.001∗ |
| FI | 33.9±31.0 | 33.6±28.0 | 35.0±27.6 | 37.4±27.7 | 0.568 | 33.6±26.8 | 35.6±30.2 | 0.545 |
| PA | 29.4±18.8 | 25.0±19.5 | 30.3±20.6 | 30.8±20.0 | 0.025∗ | 26.1±18.7 | 31.3±20.5 | 0.001∗ |
| DY | 17.9±21.7 | 12.2±18.0 | 19.1±23.7 | 19.6±25.4 | 0.039∗ | 12.7±19.3 | 21.2±23.9 | <0.001∗ |
| SL | 32.2±24.2 | 26.8±22.5 | 32.7±24.6 | 34.7±26.9 | 0.092 | 30.2±24.1 | 32.5±24.6 | 0.225 |
| AP | 23.6±23.4 | 18.3±23.0 | 26.6±26.7 | 28.8±27.9 | 0.009∗ | 21.5±23.4 | 26.3±26.7 | 0.038∗ |
| CO | 26.5±26.6 | 19.0±23.3 | 26.6±28.0 | 25.1±25.3 | 0.048∗ | 23.0±26.1 | 26.0±26.6 | 0.136 |
|
| ||||||||
| Panel B: QLQ-BR23 Questionnaire | ||||||||
|
| ||||||||
| Functional scales | ||||||||
| BRBI | 65.2±24.3 | 67.6±26.4 | 62.9±24.8 | 64.8±24.4 | 0.355 | 65.9±25.9 | 64.0±24.2 | 0.090 |
| BRSEF | 87.1±16.5 | 91.1±15.7 | 89.2±15.7 | 88.6±15.2 | 0.081 | 92.4±14.0 | 85.9±16.9 | <0.001∗ |
| BRFU | 51.0±31.5 | 53.5±33.9 | 49.7±30.9 | 53.9±27.6 | 0.600 | 51.4±30.8 | 51.6±32.0 | 0.902 |
| BRSEE | 87.5±18.1 | 91.2±17.8 | 87.6±21.6 | 87.2±19.7 | 0.153 | 92.8±14.6 | 84.3±22.4 | <0.001∗ |
| Symptom scales | ||||||||
| BRST | 24.8±16.2 | 21.8±15.7 | 26.5±17.8 | 24.8±17.1 | 0.097 | 23.0±15.6 | 26.3±17.8 | 0.023∗ |
| BRBS | 17.1±18.6 | 13.2±16.9 | 18.6±21.5 | 20.3±21.8 | 0.075 | 14.6±19.5 | 19.4±19.8 | <0.001∗ |
| BRAS | 20.4±18.4 | 17.2±18.5 | 20.7±20.8 | 24.2±20.6 | 0.083 | 17.8±19.6 | 22.4±19.4 | 0.001∗ |
| BRHL | 38.6±30.5 | 37.8±32.1 | 40.3±29.9 | 34.7±27.3 | 0.562 | 39.7±30.3 | 37.6±30.3 | 0.450 |
SD, standard deviation.
GHS, global health status; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning.
SF, social functioning; FA, fatigue; NV, nausea and vomiting; DI, diarrhoea; FI, financial difficulties; PA, pain; DY, dyspnoea.
SL, insomnia; AP, appetite loss; CO, constipation; BRBI, body image; BRSEF, sexual functioning; BRFU, future perspective.
BRSEE, sexual enjoyment; BRST, systemic therapy side effect; BRBS, breast symptoms; BRAS, arm symptoms; BRHL, upset by hair loss.